Pulmonary Arterial Hypertension Market Size, Share, Growth Analysis, By Route of Administration(Oral, Intravenous, Inhalation), By Type(Branded and Generic), By Region - Industry Forecast 2024-2031

Pulmonary Arterial Hypertension Market Drivers

Increasing Prevalence of Pulmonary Arterial Hypertension to Bolster Market Growth

• A uncommon, progressive condition known as pulmonary arterial hypertension (PAH) is characterised by elevated blood pressure in the arteries that carry blood to the lungs. Globally, the prevalence of PAH is rising as a result of ageing populations, rising rates of risk factors like obesity, and improved diagnostic techniques. This is anticipated to increase demand for PAH remedies.

• The creation of novel PAH treatments, such as prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has advanced significantly. Demand has increased as a result of these medicines' improving effectiveness and safety characteristics.

Pulmonary Arterial Hypertension Market Restraints

Limited Patient Pool might Pose as a Threat

• PAH is a rare disease, and the prevalence of the disease is relatively low compared to other chronic diseases. As a result, the patient pool for PAH is limited, which can impact the commercial viability of PAH drugs and discourage investment in drug development. The diagnosis involves several tests, including echocardiography, right heart catheterization, and pulmonary function tests. Additionally, the symptoms of PAH, such as shortness of breath and fatigue, can be non-specific and may be attributed to other conditions, leading to misdiagnosis or delayed diagnosis.